WO2002094942A1 - Method of purifying polycyclic dyes - Google Patents

Method of purifying polycyclic dyes Download PDF

Info

Publication number
WO2002094942A1
WO2002094942A1 PCT/US2002/016200 US0216200W WO02094942A1 WO 2002094942 A1 WO2002094942 A1 WO 2002094942A1 US 0216200 W US0216200 W US 0216200W WO 02094942 A1 WO02094942 A1 WO 02094942A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
hydrogen
compound
corticosteroid
formula
Prior art date
Application number
PCT/US2002/016200
Other languages
French (fr)
Other versions
WO2002094942A9 (en
Inventor
Victor Vasilievich Nazarov
Elena Nikolaevna Sidorenko
Original Assignee
Optiva, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optiva, Inc. filed Critical Optiva, Inc.
Publication of WO2002094942A1 publication Critical patent/WO2002094942A1/en
Publication of WO2002094942A9 publication Critical patent/WO2002094942A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0096—Purification; Precipitation; Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives

Definitions

  • the present invention relates to methods for making 21 -[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and also relates to intermediates useful in making such compounds.
  • Corticosteroids are known to have anti-inflammatory and immunomodulatory properties useful in the treatment of numerous diseases, including autoimmune and inflammatory diseases. However, treatment with corticosteroids may cause undesirable side-effects.
  • Steroid nitrate ester (ONO 2 ) derivatives have been used as nitric oxide donors to potentially increase the therapeutic actions of and counteract or lessen the side-effects of corticosteroids.
  • U.S. Patent No. 5,985,862 discloses pharmaceutical compositions having steroid nitrate ester (ONO 2 ) derivatives and their use in treating undesired smooth muscle contractions and inflammatory diseases. The '862 patent also discloses using nitric acid and acetic acid to form certain steroid nitrate ester derivatives.
  • WO 98/15568 entitled “Nitrate Esters of Corticoid Compounds and Pharmaceutical Applications Thereof relates to steroid-structured compounds having anti-inflammatory, immunodepressive, and angiostatic activities.
  • One of the disclosed synthetic routes includes the use of silver nitrate (AgNO 3 ) in acetonitrile.
  • silver nitrate is known to be hazardous and toxic if ingested.
  • the present invention relates to methods for making 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and also relates to intermediates useful in the methods for making such compounds.
  • a method for making a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative comprising: reacting: (a) a21-hydroxyalkyl corticosteroid;
  • R 1 is selected from the group consisting of OH, Cl, Br, F, I, and -OC(O)R 10 ; m is an integer from 0 to 4; n is an integer from 0 to 5;
  • R 2 is independently selected at each occurrence from the group consisting of amino, substituted amino, halogen, C 1-6 alkyl, C 1-6 haloalkyl, alkoxy, aryl, C 1-6 alkylamino, C 1-6 substituted alkylamino, and -OR 7 ;
  • R 3 and R 4 are independently selected at each occurrence from the group consisting of hydrogen, amino, substituted amino, halogen, C 1-6 alkyl, C ⁇ -6 haloalkyl, alkoxy, aryl, C 1-6 alkylamino, C 1-6 substituted alkylamino, and -OR ;
  • R 5 and R 6 are independently selected from the group consisting of hydrogen, amino, substituted amino, halogen, C 1-6 alkyl, C 1-6 haloalkyl, alkoxy, aryl, C 1-6 alkylamino, C 1-6 substituted alkylamino, and -OR 7 ;
  • R is independently selected at each occurrence from the group consistmg of hydrogen, -C(O)R 8 , and -C(O)NR 8 R 9 ;
  • R 8 and R 9 are independently selected at each occurrence from the group consisting of hydrogen and C ⁇ -6 alkyl;
  • R 10 is selected from the group consisting of C ⁇ -6 alkyl, chloroalkyl, alkoxy- substituted C 1-6 alkyl, and aryl;
  • a two-step method for producing a 21 -[4 '- (nitrooxyalkyl)benzoate] corticosteroid derivative comprising: (a) reacting a compound of formula (II) with acetic anhydride and nitric acid to form a compound of formula (IA)
  • a three-step method for producing a 21-[4'- (nitrooxyalkyl)benzoate] corticosteroid derivative comprising:
  • X is selected from the group consisting of Cl, Br, F, and I;
  • R 2 -R 6 are as defined above.
  • the present invention provides intermediates of formula (I) useful in the methods for making 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives as well as processes for making such intermediates.
  • the present invention relates to methods for making 21 -[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and also relates to intermediates useful in the methods for making such compounds.
  • 21 -[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and also relates to intermediates useful in the methods for making such compounds.
  • Alkyl means a branched or straight hydrocarbon group having the general formula C « H 2n+ ⁇ , where n is an integer equal to or greater than 1.
  • C ⁇ -6 alkyl means an alkyl group having from 1 to 6 carbon atoms, such as methyl, ethyl, t-butyl, and the like.
  • Amino refers to the group -NH 2 .
  • Hydroxy refers to the group -OH.
  • Thioalkyl refers to the group -S-(C 1-6 alkyl).
  • Alkoxy refers to the group -O-(C 1-6 alkyl), which includes, by way of example, methoxy, ethoxy, ra-propoxy, w ⁇ -propoxy, n-butoxy, tert-butoxy, sec-butoxy, «-pentoxy, and the like.
  • Substituted amino means an amino group in which one or both of the hydrogens are independently replaced with a C 1-6 alkyl group, hydroxy, an alkoxy group, or a thioalkyl group.
  • Halogen means chlorine (Cl), bromine (Br), iodine (I), or fluorine (F).
  • C ⁇ _ 6 haloalkyl means a C 1-6 alkyl group in which one or more of the hydrogens are independently replaced with a halogen.
  • Aryl refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinione).
  • C 1-6 alkylamino means a C ⁇ -6 alkyl group in which one or more of the hydrogens are independently replaced with an amino group.
  • C 1-6 substituted alkylamino means a C 1-6 alkyl group in which one or more of the hydrogens are independently replaced with a substituted amino group.
  • 21-hydroxy corticosteroid means any synthetic or naturally-occurring corticosteroid having a hydroxy group attached to the carbon in position 21.
  • Corticosteroids include glucocorticoids and mineralocorticoids.
  • Examples of 21-hydroxy corticosteroids include, but are not limited to, alclometasone, aldosterone, beclomethasone, betamethasone, clocortolone, hydrocortisone, budesonide, cortisone, desoximetasone, desonide, dexamethosone, flucloronide, fludrocortisone, flumethasone, flunisolide, fluocinolone acetonide, fluocortolone, fluprednisolone, flurandrenolide, halometasone, methylprednisolone, paramethasone, prednival, prednylidene, prednisolone, prednisone, triamcinolone
  • 21-hydroxy glucocorticoid means any synthetic or naturally-occurring glucocorticoid having a hydroxy group attached to the carbon in position 21.
  • 21- hydroxy glucocorticoids include, but are not limited to, beclomethasone, methylprednisolone, and paramethasone.
  • 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative means a corticosteroid derivative having a 4-(nitrooxyalkyl)benzoate attached to the carbon in the 21 position of the corticosteroid via an ester linkage with the benzoate as shown and described in formula (TV) below.
  • An example of a 21-[4'-(nitrooxyalkyl)benzoate)] corticosteroid derivative is prednisolone 21 - [4 ' -(nitrooxymethyl)benzoate] .
  • Alkoxide means a saltlike compound ROTVI, wherein R is a C ⁇ - 6 alkyl group and M is a Group I metal such as, for example, sodium or potassium. Alkoxides may be formed by reaction of an alcohol with a Group I metal such as sodium or potassium. Examples of alkoxides include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium t-butoxide, sodium t-butoxide.
  • Carbonate means a salt of carbonic acid containing the carbonate ion, CO 3 2" .
  • Examples of carbonates include, but are not limited to, sodium carbonate, potassium carbonate, lithium carbonate, and cesium carbonate.
  • C 1-6 chloroalkyl means a C 1-6 alkyl group in which one or more of the hydrogens are replaced with chlorine.
  • Alkoxy-substituted C 1-6 alkyl means a C 1-6 alkyl group in which one or more of the hydrogens are independently replaced with an alkoxy group.
  • Acid anhydride means a compound of the formula (Q-C(O)) 2 O, wherein Q is selected from the group consisting of a C 1-6 alkyl group, a C 1-6 chloroalkyl group, an alkoxy- substituted Ci-6 alkyl group, and an aryl group.
  • acid anhydrides include, but are not limited to, acetic anhydride, chloroacetic anhydride, and dichloroacetic anhydride.
  • Acid chloride means a compound of the formula Z-C(O)Cl, wherein Z is selected from the group consisting of a C ⁇ -6 alkyl group, a C 1-6 chloroalkyl group, an alkoxy-substituted C 1-6 alkyl group, and an aryl group.
  • acid chlorides include, but are not limited to, acetyl chloride, pivaloyl chloride, chloroacetyl chloride, dichloroacetyl chloride, trichloroacetyl chloride, methoxyacetyl chloride, and benzoyl chloride.
  • A-OH is a 21-hydroxy corticosteroid
  • R 1 is selected from the group consisting of OH, Cl, Br, F, I, and -OC(O)R 10 ; m is an integer from 0 to 4; n is an integer from 0 to 5;
  • R is mdependently selected at each occurrence from the group consisting of amino, substituted amino, halogen, C 1-6 alkyl, C 1-6 haloalkyl, alkoxy, aryl, C 1-6 alkylamino, C ⁇ - 6 substituted alkylamino, and -OR 7 ;
  • R 3 and R 4 are independently selected at each occurrence from the group consisting of hydrogen, amino, substituted amino, halogen, C 1-6 alkyl, C 1-6 haloalkyl, alkoxy, aryl, C 1-6 alkylamino, C 1-6 substituted alkylamino, and -OR 7 ;
  • R 5 and R 6 are independently selected from the group consisting of hydrogen, amino, substituted amino, halogen, C 1-6 alkyl, C ⁇ -6 haloalkyl, alkoxy, aryl, C 1-6 alkylamino, C 1-6 substituted alkylamino, and -OR 7 ;
  • R is independently selected at each occurrence from the group consisting of hydrogen, -C(O)R 8 , and -C(O)NR 8 R 9 ;
  • R 8 and R 9 are independently selected at each occurrence from the group consisting of hydrogen and C 1-6 alkyl
  • R 10 is selected from the group consisting of C ⁇ -6 alkyl, Ci- ⁇ chloroalkyl, alkoxy- substituted C 1-6 alkyl, and aryl.
  • the compound of formula (III) i.e., A-OH
  • A-OH is preferably a 21-hydroxy glucocorticoid, and is more preferably prednisolone, which is represented by the following formula (IIIA):
  • R 1 is preferably OH, Cl, or Br, and is more preferably OH.
  • R 1 is OH, m and n are 0, and R 5 and R 6 are hydrogen such that the compound of formula (I) is 4-(nitrooxymethyl)benzoic acid.
  • a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative is produced by reacting (a) a compound of formula (HI) (i.e., a 21- hydroxy corticosteroid A-OH), (b) a compound of formula (I), and (c) either a coupling agent or a base, depending upon the substituent R 1 .
  • Suitable coupling agents include, but are not limited to, 1,3-diisopropylcarbodiimide, 1,3- dicyclohexylcarbodiimide, l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 2- chloro-1-methylpyridinium iodide, and N, N-dimethylformamide neopentylacetal.
  • the preferred coupling agent is 1 -(3 -dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
  • Suitable bases include, but are not limited to, triethylamine, pyridine, diisopropyl ethylamine, tetramethylguanidine, l,5-diazabicyclo[4.3.0]non-5-ene, l,8-diazabicyclo[5.4.0]undec-7-ene, alkoxides, and carbonates.
  • the preferred base is triethylamine.
  • the reaction is preferably carried out in the presence of a catalyst. That is, the compound of formula (I) is preferably reacted with a 21-hydroxy corticosteroid, either a coupling agent or a base, and a suitable catalyst.
  • Suitable catalysts include, but are not limited to, 4- dimethylaminopyridine and N, N-dimethylaniline.
  • the preferred catalyst is 4- dimethylaminopyridine.
  • the reaction is also preferably carried out in an anhydrous solvent or solvent mixture such as, for example, pyridine, tetrahydrofuran, dimethylformamide, sulfolane, acetone, acetonitrile, ethyl acetate, dioxane, methyl ethyl ketone, ether, methyl t-butyl ether, chloroform, dichloromethane, or mixtures thereof.
  • the preferred solvent is acetone.
  • the reaction is typically carried out in a temperature range from about 0° C to about 50° C, and is preferably carried out at about 25° C.
  • the reaction is typically carried out for about 15 minutes to about 24 hours, and is preferably carried out from about 5 hours to about 8 hours.
  • the 21 -hydroxy corticosteroids of formula (III) used in the present invention are generally commercially available or may be obtained according to processes known in the art.
  • a compound of formula (I) above may be synthesized in one or two steps, depending upon the desired R 1 group of the compound (wherein R 1 is selected from the group consisting of OH, Cl, Br, F, I, and -OC(O)R 10 ).
  • R 1 is selected from the group consisting of OH, Cl, Br, F, I, and -OC(O)R 10 ).
  • the following synthetic scheme illustrates the one or two steps needed to produce a compound of formula (I) wherein R 1 is OH, Cl, Br, F, or I:
  • X is selected from the group consisting of Cl, Br, I, or F; and R 2 , R 3 , R 4 , R 5 , R 6 , m, and n are as defined above in the general reaction scheme.
  • This first step generates a compound of formula (I) in the general reaction scheme above wherein R 1 is OH.
  • This reaction is typically carried out in a temperature range from about -50° C to about 0° C, and is preferably carried out from about -30° C to about -10° C.
  • the reaction is typically carried out for about 1 minute to about 24 hours, and is preferably carried out for about 1 hour to about 3 hours.
  • Suitable halogenating agents include, but are not limited to, the following: chlorinating agents — thionyl chloride, N-chlorosuccinimide, oxalyl chloride, chlorine, potassium pentachloride, and potassium trichloride; brominating agents — N- bromosuccinimide, bromine, potassium tribromide, potassium pentabromide, and oxalyl bromide; fluorinating agents — potassium fluoride, polyhydrogen fluoride-pyridine, diethylaminosulfurtrifluoride, hydrogen fluoride, and cyanuric fluoride; iodinating agents — N- iodosuccinimide and iodine.
  • the reaction is typically carried in a temperature range from about - 10° C to about 30° C, and is preferably carried out in a temperature range from about 0° C to about 5° C.
  • the reaction is typically carried out for about 1 minute to about 24 hours, and is preferably carried out for about 30 minutes.
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 10 , m, and n are as defined above in the general reaction scheme.
  • the compound of formula (IA) is reacted with a suitable acid anhydride or a suitable acid halide to form the compound of formula (IC).
  • suitable acid anhydrides include, but are not limited to, acetic anhydride, chloroacetic anhydride, and dichloroacetic anhydride.
  • Suitable acid chlorides include, but are not limited to, acetyl chloride, pivaloyl chloride, chloroacetyl chloride, dichloroacetyl chloride, trichloroacetyl chloride, methoxyacetyl chloride, and benzoyl chloride.
  • the reaction is typically carried out in a temperature range from about -10° C to about 30° C, and is preferably carried out in a temperature range from about 0° C to about 5° C.
  • the reaction is typically carried out for about 1 minute to about 24 hours, and is preferably carried out for about 30 minutes.
  • a one-step method is used to produce a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative.
  • the method comprises reacting (a) a compound of formula (III), (b) a compound of formula (I), and (c) either a coupling agent (when R 1 is OH in the compound of formula (I)) or a base (when R 1 is Cl, Br, F, I, or -OC(O)R 10 in the compound of formula (I)).
  • the compound of formula (III) is prednisolone and, in formulas (I) and (TV), R 1 is OH, m and n are 0, and R 5 and R 6 are hydrogen such that the compounds of formulas (I) and (IV) are respectively 4-(nitrooxymethyl)benzoic acid and prednisolone 21-[(4'- (nitrooxymethyl)benzoate].
  • Prednisolone 21-[(4'-(nitrooxymethyl)benzoate] is shown below as formula (IV A):
  • a two-step method is used wherein a compound of formula (II) is reacted with nitric acid and acetic anhydride to form a nitroester acid of compound (IA).
  • the compound of formula (IA) is reacted with a 21-hydroxy corticosteroid (the compound of formula (HI)) and a coupling agent to form a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative of formula (IV).
  • the synthetic scheme is shown as follows:
  • the 21-hydroxy corticosteroid of formula (I) is prednisolone and, in formulas (II), (IA), and (TV), m and n are 0 and R 5 and R 6 are hydrogen such that the compounds of formulas (II), (IA), and (IV) are respectively 4-(hydroxymethyl)benzoic acid, 4- (nitrooxymethyl)benzoic acid, and prednisolone 21-[(4'-(nitrooxymethyl)benzoate].
  • a three-step method is used to generate a 21-[4'- (nitrooxyalkyl)benzoate] corticosteroid derivative.
  • a compound of formula (II) is reacted with nitric acid and acetic anhydride to form a nitroester acid of compound (IA).
  • the compound of formula (IA) is then halogenated with a suitable halogenating agent to form an acid halide of formula (IB).
  • the acid halide of formula (IB) is then reacted with a 21-hydroxy corticosteroid (the compound of formula (HI)) and a base to form a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative of formula (IV).
  • the synthetic scheme is shown as follows:
  • the 21-hydroxy corticosteroid of formula (HI) is prednisolone and, in formulas (II), (IA), (IB), and (IV), m and n are 0, R 5 and R 6 are hydrogen, and, in formula (IB), X is Cl or Br such that the compounds of formulas (II), (IA), (IB), and (TV) are respectively 4- (hydroxymethyl)benzoic acid, 4-(nitrooxymethyl)benzoic acid, 4-(nitrooxymethyl)benzoyl chloride or 4-(nitrooxymethyl)benzoyl bromide, and prednisolone 21-[(4'- (nitrooxymethyl)benzoate] .
  • another three-step method is used to generate a 21-[4'- (nitrooxyalkyl)benzoate] corticosteroid derivative.
  • a compound of formula (H) is reacted with nitric acid and acetic anhydride to form a nitroester acid of compound (IA).
  • the compound of formula (IA) is then reacted with a suitable acid anhydride or a suitable acid chloride to form a compound of formula (IC).
  • the compound of formula (IC) is then reacted with a 21-hydroxy corticosteroid (the compound of formula (HI)) and a base to form a 21 -[4'- (nitrooxyalkyl)benzoate] corticosteroid derivative of formula (IV).
  • the synthetic scheme is shown as follows:
  • the 21-hydroxy corticosteroid of formula (in) is prednisolone and, in formulas (H), (IA), (IC), and (IV), m and n are 0 and R 5 and R 6 are hydrogen such that the compounds of formulas (II), (IA), and (TV) are respectively 4-(hydroxymethyl)benzoic acid, 4- (nitrooxymethyl)benzoic acid, and prednisolone 21-[(4'-(nitrooxymethyl)benzoate].
  • Suitable and/or prefened coupling agents, bases, halogenating agents, acid anhydrides, and acid chlorides as well as other suitable and/or preferred 21-hydroxy corticosteroids and compound substituents for each of these aspects of the invention are described above in the general reaction scheme and in the description of the materials.
  • Example I Two-step process for svnthesis of prednisolone 21-[4'-(nitrooxymethyl) benzoate] Step 1: Svnthesis of 4-(nitrooxymethy ⁇ benzoic acid
  • Nitric acid 760 ml was cooled to -30 °C and acetic anhydride (1520 ml) was added portionwise with stirring. This mixture was stirred at -30 °C for 15 minutes.
  • 4- (Hydroxymethyl)benzoic acid 400 g, 2.63 moles) slurried in acetic anhydride (1520 ml) was added and the beaker was rinsed with the remaining acetic anhydride (800 ml). After 2 hours at — 10 °C, the reaction was complete as evidenced by high performance liquid chromatography (HPLC) analysis. The reaction mixture was poured into water (10 L) and stirred for 30 minutes.
  • HPLC high performance liquid chromatography
  • Step 2 Svnthesis of Prednisolone 21-[4 nifrooxymethyI)benzoatel

Abstract

The disclosed invention pertains to technology of fabricating and purifying synthetic dyes and may be used in various areas of industry and national economy, particularly in fabrication of materials for polarizing coatings of various purposes. In this method of purifying polycyclic dyes, the original dye is processed at least once with concentrated hydrochloric acid in the presence of at least one nitrogen-containing organic compound, such as heterocyclic base and/or aliphatic and/or aromatic amine, and/or quaternary ammonium salt in the amount of 0.1-5% of the weight of the dye at 50-100°C with subsequent filtration. After that, the obtained press-cake is processed at least once with boiling glacial ascetic acid with subsequent hot filtration of the suspension. Obtained sediment is washed with distilled water, after which the sediment is repulped in water, filtered and dried.

Description

METHODS OF MAKING 21-[4'-(NITROOXYALKYL)BENZOATE] CORTICOSTEROID DERIVATIVES AND INTERMEDIATES USEFUL IN THE
SYNTHESIS THEREOF
FIELD OF THE INVENTION
[0001] The present invention relates to methods for making 21 -[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and also relates to intermediates useful in making such compounds.
BACKGROUND OF THE INVENTION
[0002] Corticosteroids are known to have anti-inflammatory and immunomodulatory properties useful in the treatment of numerous diseases, including autoimmune and inflammatory diseases. However, treatment with corticosteroids may cause undesirable side-effects. [0003] Steroid nitrate ester (ONO2) derivatives have been used as nitric oxide donors to potentially increase the therapeutic actions of and counteract or lessen the side-effects of corticosteroids. For example, U.S. Patent No. 5,985,862 discloses pharmaceutical compositions having steroid nitrate ester (ONO2) derivatives and their use in treating undesired smooth muscle contractions and inflammatory diseases. The '862 patent also discloses using nitric acid and acetic acid to form certain steroid nitrate ester derivatives.
[0004] WO 98/15568 entitled "Nitrate Esters of Corticoid Compounds and Pharmaceutical Applications Thereof relates to steroid-structured compounds having anti-inflammatory, immunodepressive, and angiostatic activities. One of the disclosed synthetic routes includes the use of silver nitrate (AgNO3) in acetonitrile. However, silver nitrate is known to be hazardous and toxic if ingested.
[0005] It would be desirable to provide an efficient and low-cost method of making 21-[4'- (nitrooxyalkyl)benzoate] corticosteroid derivatives without using heavy metal compounds such as silver nitrate.
SUMMARY OF THE INVENTION
[0006] The present invention relates to methods for making 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and also relates to intermediates useful in the methods for making such compounds.
[0007] In one aspect, a method for making a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative is provided comprising: reacting: (a) a21-hydroxyalkyl corticosteroid;
(b) a compound of formula (I)
Figure imgf000003_0001
wherein:
R1 is selected from the group consisting of OH, Cl, Br, F, I, and -OC(O)R10; m is an integer from 0 to 4; n is an integer from 0 to 5;
R2 is independently selected at each occurrence from the group consisting of amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R3 and R4 are independently selected at each occurrence from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, Cι-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR ;
R5 and R6 are independently selected from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R is independently selected at each occurrence from the group consistmg of hydrogen, -C(O)R8, and -C(O)NR8R9;
R8 and R9 are independently selected at each occurrence from the group consisting of hydrogen and Cι-6 alkyl; and
R10 is selected from the group consisting of Cι-6 alkyl,
Figure imgf000003_0002
chloroalkyl, alkoxy- substituted C1-6 alkyl, and aryl; and
(c) a coupling agent or a base; with the proviso that when R1 is OH the coupling agent is used and when R1 is Cl, Br, F, I, or -OC(O)R10 the base is used. [0008] In another aspect of the invention, a two-step method for producing a 21 -[4 '- (nitrooxyalkyl)benzoate] corticosteroid derivative is provided comprising: (a) reacting a compound of formula (II)
Figure imgf000004_0001
with acetic anhydride and nitric acid to form a compound of formula (IA)
Figure imgf000004_0002
and
(b) reacting the compound of formula (IA) with a 21-hydroxyalkyl corticosteroid and a coupling agent to produce a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative; wherein m, n, and R2-R6 are as defined above.
[0009] In yet another aspect, a three-step method for producing a 21-[4'- (nitrooxyalkyl)benzoate] corticosteroid derivative is provided comprising:
(a) reacting a compound of formula (H)
Figure imgf000004_0003
with acetic anhydride and nitric acid to form a compound of formula (IA)
Figure imgf000005_0001
(b) reacting the compound of formula (IA) with a halogenating agent to form a compound of formula (IB)
Figure imgf000005_0002
wherein X is selected from the group consisting of Cl, Br, F, and I; and
(c) reacting the compound of formula (IB) with a 21-hydroxyalkyl corticosteroid and a base to produce a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative; wherein m, n, and
R2-R6 are as defined above.
[0010] In a further aspect, another three-step method for producing a 21 -[4'-
(nitrooxyalkyl)benzoate] corticosteroid derivative is provided comprising: (a) reacting a compound of formula (TJ)
Figure imgf000005_0003
with acetic anhydride and nitric acid to form a compound of formula (IA)
Figure imgf000006_0001
(b) reacting the compound of formula (IA) with an acid anhydride or an acid chloride to form a compound of formula (IC)
Figure imgf000006_0002
and
(c) reacting the compound of formula (IC) with a 21-hydroxyalkyl corticosteroid and a base to produce a 21-[4'-(nitrooxyaIkyl)benzoate] corticosteroid derivative; wherein m, n, and R2-R6, and R10 are as defined above.
[0011] In yet a further aspect, the present invention provides intermediates of formula (I) useful in the methods for making 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives as well as processes for making such intermediates.
DETAILED DESCRIPTION OF THE INVENTION
[0012] The present invention relates to methods for making 21 -[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and also relates to intermediates useful in the methods for making such compounds. Prior to describing this invention in further detail, however, the following terms will first be defined. Definitions:
[0013] Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:
[0014] "Alkyl" means a branched or straight hydrocarbon group having the general formula C«H2n+ι, where n is an integer equal to or greater than 1. [0015] "Cι-6 alkyl" means an alkyl group having from 1 to 6 carbon atoms, such as methyl, ethyl, t-butyl, and the like. [0016] "Amino" refers to the group -NH2. [0017] "Hydroxy" refers to the group -OH. [0018] "Thioalkyl" refers to the group -S-(C1-6 alkyl).
[0019] "Alkoxy" refers to the group -O-(C1-6 alkyl), which includes, by way of example, methoxy, ethoxy, ra-propoxy, wσ-propoxy, n-butoxy, tert-butoxy, sec-butoxy, «-pentoxy, and the like.
[0020] "Substituted amino" means an amino group in which one or both of the hydrogens are independently replaced with a C1-6 alkyl group, hydroxy, an alkoxy group, or a thioalkyl group. [0021] "Halogen" means chlorine (Cl), bromine (Br), iodine (I), or fluorine (F). [0022] "Cι_6 haloalkyl" means a C1-6 alkyl group in which one or more of the hydrogens are independently replaced with a halogen.
[0023] "Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinione). [0024] "C1-6 alkylamino" means a Cι-6 alkyl group in which one or more of the hydrogens are independently replaced with an amino group.
[0025] "C1-6 substituted alkylamino" means a C1-6 alkyl group in which one or more of the hydrogens are independently replaced with a substituted amino group.
[0026] "21-hydroxy corticosteroid" means any synthetic or naturally-occurring corticosteroid having a hydroxy group attached to the carbon in position 21. Corticosteroids include glucocorticoids and mineralocorticoids. Examples of 21-hydroxy corticosteroids include, but are not limited to, alclometasone, aldosterone, beclomethasone, betamethasone, clocortolone, hydrocortisone, budesonide, cortisone, desoximetasone, desonide, dexamethosone, flucloronide, fludrocortisone, flumethasone, flunisolide, fluocinolone acetonide, fluocortolone, fluprednisolone, flurandrenolide, halometasone, methylprednisolone, paramethasone, prednival, prednylidene, prednisolone, prednisone, triamcinolone, and triamcinolone acetonide. [0027] "21-hydroxy glucocorticoid" means any synthetic or naturally-occurring glucocorticoid having a hydroxy group attached to the carbon in position 21. Examples of 21- hydroxy glucocorticoids include, but are not limited to, beclomethasone, methylprednisolone, and paramethasone. [0028] "21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative" means a corticosteroid derivative having a 4-(nitrooxyalkyl)benzoate attached to the carbon in the 21 position of the corticosteroid via an ester linkage with the benzoate as shown and described in formula (TV) below. An example of a 21-[4'-(nitrooxyalkyl)benzoate)] corticosteroid derivative is prednisolone 21 - [4 ' -(nitrooxymethyl)benzoate] .
[0029] "Alkoxide" means a saltlike compound ROTVI, wherein R is a Cι-6 alkyl group and M is a Group I metal such as, for example, sodium or potassium. Alkoxides may be formed by reaction of an alcohol with a Group I metal such as sodium or potassium. Examples of alkoxides include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium t-butoxide, sodium t-butoxide.
[0030] "Carbonate" means a salt of carbonic acid containing the carbonate ion, CO3 2". Examples of carbonates include, but are not limited to, sodium carbonate, potassium carbonate, lithium carbonate, and cesium carbonate.
[0031] "C1-6 chloroalkyl" means a C1-6 alkyl group in which one or more of the hydrogens are replaced with chlorine.
[0032] "Alkoxy-substituted C1-6 alkyl" means a C1-6 alkyl group in which one or more of the hydrogens are independently replaced with an alkoxy group.
[0033] "Acid anhydride" means a compound of the formula (Q-C(O))2O, wherein Q is selected from the group consisting of a C1-6 alkyl group, a C1-6 chloroalkyl group, an alkoxy- substituted Ci-6 alkyl group, and an aryl group. Examples of acid anhydrides include, but are not limited to, acetic anhydride, chloroacetic anhydride, and dichloroacetic anhydride. [0034] "Acid chloride" means a compound of the formula Z-C(O)Cl, wherein Z is selected from the group consisting of a Cι-6 alkyl group, a C1-6 chloroalkyl group, an alkoxy-substituted C1-6 alkyl group, and an aryl group. Examples of acid chlorides include, but are not limited to, acetyl chloride, pivaloyl chloride, chloroacetyl chloride, dichloroacetyl chloride, trichloroacetyl chloride, methoxyacetyl chloride, and benzoyl chloride.
General Reaction Scheme
[0035] The general reaction scheme of the invention for producing a 21-[4'-
(nitrooxyalkyl)benzoate] corticosteroid derivative is represented as follows:
Figure imgf000009_0001
© (IV) wherein:
A-OH is a 21-hydroxy corticosteroid;
R1 is selected from the group consisting of OH, Cl, Br, F, I, and -OC(O)R10; m is an integer from 0 to 4; n is an integer from 0 to 5;
R is mdependently selected at each occurrence from the group consisting of amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, Cι-6 substituted alkylamino, and -OR7;
R3 and R4 are independently selected at each occurrence from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R5 and R6 are independently selected from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, Cι-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R is independently selected at each occurrence from the group consisting of hydrogen, -C(O)R8, and -C(O)NR8R9;
R8 and R9 are independently selected at each occurrence from the group consisting of hydrogen and C1-6 alkyl; and
R10 is selected from the group consisting of Cι-6 alkyl, Ci-β chloroalkyl, alkoxy- substituted C1-6 alkyl, and aryl. [0036] The compound of formula (III) (i.e., A-OH) is preferably a 21-hydroxy glucocorticoid, and is more preferably prednisolone, which is represented by the following formula (IIIA):
Figure imgf000010_0001
[0037] R1 is preferably OH, Cl, or Br, and is more preferably OH. In one preferred embodiment, in the compound of formula (I), R1 is OH, m and n are 0, and R5 and R6 are hydrogen such that the compound of formula (I) is 4-(nitrooxymethyl)benzoic acid. [0038] As shown in the general reaction scheme above, a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative is produced by reacting (a) a compound of formula (HI) (i.e., a 21- hydroxy corticosteroid A-OH), (b) a compound of formula (I), and (c) either a coupling agent or a base, depending upon the substituent R1. By way of example, when R1 is OH, (a) a compound of formula (I), (b) a corticosteroid of formula (111), and (c) a suitable coupling agent are reacted. Suitable coupling agents include, but are not limited to, 1,3-diisopropylcarbodiimide, 1,3- dicyclohexylcarbodiimide, l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 2- chloro-1-methylpyridinium iodide, and N, N-dimethylformamide neopentylacetal. The preferred coupling agent is 1 -(3 -dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. [0039] By way of further example, when R1 is Br, Cl, F, I, or -OC(O)R10 (a) a compound of formula (I), (b) a corticosteroid of formula (HI), and (c) a suitable base are reacted. Suitable bases include, but are not limited to, triethylamine, pyridine, diisopropyl ethylamine, tetramethylguanidine, l,5-diazabicyclo[4.3.0]non-5-ene, l,8-diazabicyclo[5.4.0]undec-7-ene, alkoxides, and carbonates. The preferred base is triethylamine.
[0040] The reaction is preferably carried out in the presence of a catalyst. That is, the compound of formula (I) is preferably reacted with a 21-hydroxy corticosteroid, either a coupling agent or a base, and a suitable catalyst. Suitable catalysts include, but are not limited to, 4- dimethylaminopyridine and N, N-dimethylaniline. The preferred catalyst is 4- dimethylaminopyridine.
[0041] The reaction is also preferably carried out in an anhydrous solvent or solvent mixture such as, for example, pyridine, tetrahydrofuran, dimethylformamide, sulfolane, acetone, acetonitrile, ethyl acetate, dioxane, methyl ethyl ketone, ether, methyl t-butyl ether, chloroform, dichloromethane, or mixtures thereof. The preferred solvent is acetone. [0042] The reaction is typically carried out in a temperature range from about 0° C to about 50° C, and is preferably carried out at about 25° C. The reaction is typically carried out for about 15 minutes to about 24 hours, and is preferably carried out from about 5 hours to about 8 hours.
Materials
[0043] The 21 -hydroxy corticosteroids of formula (III) used in the present invention are generally commercially available or may be obtained according to processes known in the art. [0044] A compound of formula (I) above may be synthesized in one or two steps, depending upon the desired R1 group of the compound (wherein R1 is selected from the group consisting of OH, Cl, Br, F, I, and -OC(O)R10). The following synthetic scheme illustrates the one or two steps needed to produce a compound of formula (I) wherein R1 is OH, Cl, Br, F, or I:
halogenating agent
Figure imgf000011_0002
Figure imgf000011_0001
(ID (IA) (IB) wherein:
X is selected from the group consisting of Cl, Br, I, or F; and R2, R3, R4, R5, R6, m, and n are as defined above in the general reaction scheme. [0045] In the first step, the compound of formula (TJ) is reacted with nitric acid (HNO3) and acetic anhydride (Ac2O) to form the nitroester acid compound of formula (IA). This first step generates a compound of formula (I) in the general reaction scheme above wherein R1 is OH. This reaction is typically carried out in a temperature range from about -50° C to about 0° C, and is preferably carried out from about -30° C to about -10° C. The reaction is typically carried out for about 1 minute to about 24 hours, and is preferably carried out for about 1 hour to about 3 hours.
[0046] In order to form a compound of formula (I) in the general reaction scheme above wherein R1 is Cl, Br, I, or F (i.e., R1 is X), the second step must be carried out. When R1 is Cl, Br, I, or F in the compound of formula (I) (i.e., when X is Cl, Br, I, or F in the compound of formula (IB)), the compound of formula (IA) is halogenated with a suitable halogenating agent to form the acid halide of formula (IB). Suitable halogenating agents include, but are not limited to, the following: chlorinating agents — thionyl chloride, N-chlorosuccinimide, oxalyl chloride, chlorine, potassium pentachloride, and potassium trichloride; brominating agents — N- bromosuccinimide, bromine, potassium tribromide, potassium pentabromide, and oxalyl bromide; fluorinating agents — potassium fluoride, polyhydrogen fluoride-pyridine, diethylaminosulfurtrifluoride, hydrogen fluoride, and cyanuric fluoride; iodinating agents — N- iodosuccinimide and iodine. The reaction is typically carried in a temperature range from about - 10° C to about 30° C, and is preferably carried out in a temperature range from about 0° C to about 5° C. The reaction is typically carried out for about 1 minute to about 24 hours, and is preferably carried out for about 30 minutes.
[0047] In order to form a compound of formula (I) in the general reaction scheme above wherein R1 is -OC(O)R10, an alternate second step must be carried out. The following synthetic scheme illustrates the first step described above and the alternate second step:
Figure imgf000012_0001
rø (IA) (IC) wherein:
R2, R3, R4, R5, R6, R10, m, and n are as defined above in the general reaction scheme. After performing the first step as described above, the compound of formula (IA) is reacted with a suitable acid anhydride or a suitable acid halide to form the compound of formula (IC). Suitable acid anhydrides include, but are not limited to, acetic anhydride, chloroacetic anhydride, and dichloroacetic anhydride. Suitable acid chlorides include, but are not limited to, acetyl chloride, pivaloyl chloride, chloroacetyl chloride, dichloroacetyl chloride, trichloroacetyl chloride, methoxyacetyl chloride, and benzoyl chloride. The reaction is typically carried out in a temperature range from about -10° C to about 30° C, and is preferably carried out in a temperature range from about 0° C to about 5° C. The reaction is typically carried out for about 1 minute to about 24 hours, and is preferably carried out for about 30 minutes. Illustrative embodiments
[0048] In one aspect of the invention and as discussed above in the general reaction scheme, a one-step method is used to produce a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative. As discussed above, the method comprises reacting (a) a compound of formula (III), (b) a compound of formula (I), and (c) either a coupling agent (when R1 is OH in the compound of formula (I)) or a base (when R1 is Cl, Br, F, I, or -OC(O)R10 in the compound of formula (I)). In a preferred embodiment, the compound of formula (III) is prednisolone and, in formulas (I) and (TV), R1 is OH, m and n are 0, and R5 and R6 are hydrogen such that the compounds of formulas (I) and (IV) are respectively 4-(nitrooxymethyl)benzoic acid and prednisolone 21-[(4'- (nitrooxymethyl)benzoate]. Prednisolone 21-[(4'-(nitrooxymethyl)benzoate] is shown below as formula (IV A):
Figure imgf000013_0001
[0049] In another aspect, a two-step method is used wherein a compound of formula (II) is reacted with nitric acid and acetic anhydride to form a nitroester acid of compound (IA). The compound of formula (IA) is reacted with a 21-hydroxy corticosteroid (the compound of formula (HI)) and a coupling agent to form a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative of formula (IV). The synthetic scheme is shown as follows:
Figure imgf000013_0002
(ID (IA) (IV)
In a preferred embodiment, the 21-hydroxy corticosteroid of formula (I) is prednisolone and, in formulas (II), (IA), and (TV), m and n are 0 and R5 and R6 are hydrogen such that the compounds of formulas (II), (IA), and (IV) are respectively 4-(hydroxymethyl)benzoic acid, 4- (nitrooxymethyl)benzoic acid, and prednisolone 21-[(4'-(nitrooxymethyl)benzoate]. [0050] In yet another aspect, a three-step method is used to generate a 21-[4'- (nitrooxyalkyl)benzoate] corticosteroid derivative. A compound of formula (II) is reacted with nitric acid and acetic anhydride to form a nitroester acid of compound (IA). The compound of formula (IA) is then halogenated with a suitable halogenating agent to form an acid halide of formula (IB). The acid halide of formula (IB) is then reacted with a 21-hydroxy corticosteroid (the compound of formula (HI)) and a base to form a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative of formula (IV). The synthetic scheme is shown as follows:
Figure imgf000014_0001
(ID (IA)
Figure imgf000014_0002
In a preferred embodiment, the 21-hydroxy corticosteroid of formula (HI) is prednisolone and, in formulas (II), (IA), (IB), and (IV), m and n are 0, R5 and R6 are hydrogen, and, in formula (IB), X is Cl or Br such that the compounds of formulas (II), (IA), (IB), and (TV) are respectively 4- (hydroxymethyl)benzoic acid, 4-(nitrooxymethyl)benzoic acid, 4-(nitrooxymethyl)benzoyl chloride or 4-(nitrooxymethyl)benzoyl bromide, and prednisolone 21-[(4'- (nitrooxymethyl)benzoate] .
[0051] In a further aspect, another three-step method is used to generate a 21-[4'- (nitrooxyalkyl)benzoate] corticosteroid derivative. A compound of formula (H) is reacted with nitric acid and acetic anhydride to form a nitroester acid of compound (IA). The compound of formula (IA) is then reacted with a suitable acid anhydride or a suitable acid chloride to form a compound of formula (IC). The compound of formula (IC) is then reacted with a 21-hydroxy corticosteroid (the compound of formula (HI)) and a base to form a 21 -[4'- (nitrooxyalkyl)benzoate] corticosteroid derivative of formula (IV). The synthetic scheme is shown as follows:
Figure imgf000015_0001
In a preferred embodiment, the 21-hydroxy corticosteroid of formula (in) is prednisolone and, in formulas (H), (IA), (IC), and (IV), m and n are 0 and R5 and R6 are hydrogen such that the compounds of formulas (II), (IA), and (TV) are respectively 4-(hydroxymethyl)benzoic acid, 4- (nitrooxymethyl)benzoic acid, and prednisolone 21-[(4'-(nitrooxymethyl)benzoate]. [0052] Suitable and/or prefened coupling agents, bases, halogenating agents, acid anhydrides, and acid chlorides as well as other suitable and/or preferred 21-hydroxy corticosteroids and compound substituents for each of these aspects of the invention are described above in the general reaction scheme and in the description of the materials.
EXAMPLES
[0053] The invention will be further explained by the following illustrative example that is intended to be non-limiting.
Example I: Two-step process for svnthesis of prednisolone 21-[4'-(nitrooxymethyl) benzoate] Step 1: Svnthesis of 4-(nitrooxymethyπbenzoic acid
Figure imgf000016_0001
[0054] Nitric acid (760 ml) was cooled to -30 °C and acetic anhydride (1520 ml) was added portionwise with stirring. This mixture was stirred at -30 °C for 15 minutes. 4- (Hydroxymethyl)benzoic acid (400 g, 2.63 moles) slurried in acetic anhydride (1520 ml) was added and the beaker was rinsed with the remaining acetic anhydride (800 ml). After 2 hours at — 10 °C, the reaction was complete as evidenced by high performance liquid chromatography (HPLC) analysis. The reaction mixture was poured into water (10 L) and stirred for 30 minutes. The resulting white solid was filtered and washed with water (3x1.5 L) and dried overnight. The reaction was repeated and the combined resulting white solid (859 g, 83 % yield), which was approximately 100 % pure by HPLC analysis, was used without further purification in Step 2 described below.
[0055] The white solid (4-(nitrooxymethyl)benzoic acid) was characterized using proton nuclear magnetic resonance (1H NMR). The following chemical shifts were reported (referenced from dimethyl sulfoxide (DMSO)), as follows in parts per million (ppm): 1H NMR (DMSO) 5.665 (2H, s), 7.581 (2H, d), 7.984 (2H, d).
Step 2: Svnthesis of Prednisolone 21-[4 nifrooxymethyI)benzoatel
Figure imgf000016_0002
[0056] Prednisolone (1104 g, 3.06 moles), 4-(nitrooxymethyl)benzoic acid (785.5 g, 3.98 moles), and catalytic 4-(dimethylamino)pyridine (10 g) were combined in acetone (11 L). l-(3- dime ylaminopropyl)-3-ethylcarbodiimide hydrochloride (618 g, 3.98 moles) was added in one portion. After 5 hours, the reaction was worked up. The solvent was removed from the reaction mixture, water (4 L) was added, and the mixture was stirred for 15 minutes, after which time the water was removed. Ethyl acetate: tetrahydrofuran (8:2) (3L) was added and the mixture was stirred for 30 minutes. This washing was repeated with 4 L of solvent (i.e., ethyl acetate: tetrahydrofuran (8:2)). The mixture was filtered and the resulting white solid was dried. The white solid (803 g, 48 % yield) was 94.6 % pure by HPLC analysis and had a melting point of 221-223 °C. The white solid was characterized using proton nuclear magnetic resonance (1H NMR). The following chemical shifts were reported, (referenced from dimethyl sulfoxide (DMSO)), as follows in parts per million (ppm): 1H NMR (DMSO) 0.838 (3H, s), 1.402 (3H, s), 5.19 (2H, dd), 5.687 (2H, s), 5.924 (1H, s), 6.174 (1H, d), 7.339 (1H, d), 7.639 (2H, d), 8.042 (2H, d).
[0057] While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the invention.

Claims

WHAT IS CLAIMED IS:
1. A method for making a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative comprising: reacting:
(a) a 21-hydroxyalkyl corticosteroid;
(b) a compound of formula (I)
Figure imgf000018_0001
wherein:
R1 is selected from the group consisting of OH, Cl, Br, F, I, and -OC(O)R10; m is an integer from 0 to 4; n is an integer from 0 to 5;
R2 is independently selected at each occurrence from the group consisting of amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R3 and R4 are independently selected at each occurrence from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R5 and R6 are independently selected from the group consisting of hydrogen, amino, substituted amino, halogen, Cι-6 alkyl, Ci-β haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R7 is independently selected at each occurrence from the group consisting of hydrogen, -C(O)R8, and -C(O)NR8R9;
R and R are independently selected at each occurrence from the group consisting of hydrogen and Ci-β alkyl; and
R10 is selected from the group consisting of C1-6 alkyl, Cι-6 chloroalkyl, alkoxy- substituted C1-6 alkyl, and aryl; and (c) a coupling agent or a base; with the proviso that when R1 is OH the coupling agent is used and when R1 is Cl, Br, F, I, or -OC(O)R10 the base is used.
2. The method of claim 1, wherein R1 is OH and the coupling agent is selected from the group consisting of 1,3-diisopropylcarbodiimide, 1,3-dicyclohexylcarbodiimide, l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 2-chloro-l-methylpyridinium iodide, and N, N-dimethylformamide neopentylacetal.
3. The method of claim 1, wherein R1 is Cl, Br, F, I, or -OC(O)R10 and the base is selected from the group consisting of triethylamine, pyridine, diisopropyl ethylamine, tetramethylguanidine, l,5-diazabicyclo[4.3.0]non-5-ene, l,8-diazabicyclo[5.4.0]undec-7-ene, alkoxides, and carbonates.
4. The method of claim 1, further comprising reacting (a), (b), and (c) with (d) a catalyst.
5. The method of claim 4, wherein the catalyst comprises 4-dimethylaminopyridine.
6. The method of claim 1, wherein the 21-hydroxy corticosteroid is selected from the group consisting of alclometasone, aldosterone, beclomethasone, betamethasone, clocortolone, hydrocortisone, budesonide, cortisone, desoximetasone, desonide, dexamethosone, flucloronide, fludrocortisone, flumethasone, flunisolide, fluocinolone acetonide, fluocortolone, fluprednisolone, flurandrenolide, halometasone, methylprednisolone, paramethasone, prednival, prednylidene, prednisolone, prednisone, triamcinolone, and triamcinolone acetonide.
7. The method of claim 1, wherein the 21-hydroxy corticosteroid comprises a 21- hydroxy glucocorticoid.
8. The method of claim 7, wherein the 21-hydroxy glucocorticoid comprises prednisolone.
9. The method of claim 1, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
10. The method of claim 1, further comprising reacting (a), (b), and (c) with (d) a catalyst, and wherein R1 is OH and the coupling agent is selected from the group consisting of 1,3-diisopropylcarbodiimide, 1,3-dicyclohexylcarbodiimide, l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride, 2-chloro-l-methylpyridinium iodide, and N, N- dimethylformamide neopentylacetal.
11. The method of claim 10, wherein the 21-hydroxy corticosteroid comprises a 21- hydroxy glucocorticoid.
12. The method of claim 11, wherein the 21-hydroxy glucocorticoid comprises prednisolone.
13. The method of claim 12, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
14. The method of claim 13, wherein the catalyst comprises 4-dimethylaminopyridine and the coupling agent comprises l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
15. The method of claim 1, further comprising reacting (a), (b), and (c) with (d) a catalyst, and wherein R1 is Cl or Br.
16. The method of claim 15, wherein the 21-hydroxy corticosteroid comprises a 21- hydroxy glucocorticoid.
17. The method of claim 16, wherein the 21-hydroxy glucocorticoid comprises prednisolone.
18. The method of claim 17, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
19. The method of claim 18, wherein the catalyst comprises 4-dimethylaminopyridine and the base comprises triethylamine.
20. A method for producing a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative comprising:
(a) reacting a compound of formula (H)
Figure imgf000021_0001
wherein: m is an integer from 0 to 4; n is an integer from 0 to 5;
R is independently selected at each occurcence from the group consisting of amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R and R are independently selected at each occurrence from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R5 and R6 are independently selected from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR ;
R7 is independently selected at each occurrence from the group consisting of hydrogen, -C(O)R8, and -C(O)NR8R9; and
R8 and R9 are independently selected at each occurrence from the group consisting of hydrogen and Cι-6 alkyl; with acetic anhydride and nitric acid to form a compound of formula (IA)
Figure imgf000021_0002
wherein m, n, R >2 , R τ> 3 , R τ>4 , R r,5 , and R are as above in the compound of formula (II); and (b) reacting the compound of formula (IA) with a 21-hydroxyalkyl corticosteroid and a coupling agent to produce a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative.
21. The method of claim 20, wherein the coupling agent is selected from the group consisting of 1,3-diisopropylcarbodiimide, 1,3-dicyclohexylcarbodiimide, l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 2-chloro-l-methylpyridinium iodide, and N, N-dimethylformamide neopentylacetal.
22. The method of claim 20, wherein the corticosteroid, the compound of formula (IA), and the coupling agent are reacted with a catalyst.
23. The method of claim 22, wherein the catalyst comprises 4-dimethylaminopyridine.
24. The method of claim 20, wherein the corticosteroid is selected from the group consisting of alclometasone, aldosterone, beclomethasone, betamethasone, clocortolone, hydrocortisone, budesonide, cortisone, desoximetasone, desonide, dexamethosone, flucloronide, fludrocortisone, flumethasone, flunisolide, fluocinolone acetonide, fluocortolone, fluprednisolone, flurandrenolide, halometasone, methylprednisolone, paramethasone, prednival, prednylidene, prednisolone, prednisone, triamcinolone, and triamcinolone acetonide.
25. The method of claim 20, wherein the 21-hydroxy corticosteroid comprises a 21- hydroxy glucocorticoid.
26. The method of claim 25, wherein the 21-hydroxy glucocorticoid comprises prednisolone.
27. The method of claim 20, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
28. The method of claim 20, wherein: the coupling agent is selected from the group consisting of 1,3-diisopropylcarbodiimide, 1,3-dicyclohexylcarbodiimide, l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 2-chloro-l-methylpyridinium iodide, andN, N-dimethylformamide neopentylacetal; and the corticosteroid, the compound of formula (IA), and the coupling agent are reacted with a catalyst.
29. The method of claim 28, wherein the 21-hydroxy corticosteroid comprises a 21- hydroxy glucocorticoid.
30. The method of claim 29, wherein the 21-hydroxy glucocorticoid comprises prednisolone.
31. The method of claim 30, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
32. The method of claim 31, wherein the catalyst comprises 4-dimethylaminopyridine and the coupling agent comprises l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
33. A method for producing a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative comprising:
(a) reacting a compound of formula (II)
Figure imgf000023_0001
wherein: m is an integer from 0 to 4; n is an integer from 0 to 5;
R2 is independently selected at each occurrence from the group consisting of amino, substituted amino, halogen, C1-6 alkyl, Ci-β haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R3 and R4 are independently selected at each occunence from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, Cι-6 alkylamino, C1-6 substituted alkylamino, and -OR7; R5 and R6 are independently selected from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1- substituted alkylamino, and -OR7;
R7 is independently selected at each occurrence from the group consisting of hydrogen, -C(O)R8, and -C(O)NR8R9; and
R and R are independently selected at each occurrence from the group consisting of hydrogen and C\.6 alkyl; with acetic anhydride and nitric acid to form a compound of formula (IA)
Figure imgf000024_0001
wherein m, n, R >2 , r R>3 , τ R>4 , τ R>5 , a „„nd j - Rπβ are as above in the compound of formula (II); (b) reacting the compound of formula (IA) with a halogenating agent to form a compound of formula (IB)
Figure imgf000024_0002
wherein:
X is selected from the group consisting of Cl, Br, F, and I; and . m, n, R2, R3, R4, R5, and R6 are as above in the compound of formula (H); and (c) reacting the compound of formula (IB) with a 21-hydroxyalkyl corticosteroid and a base to produce a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative.
34. The method of claim 33, wherein the base is selected from the group consisting of trimethylamine, pyridine, diisopropyl efhylamine, tetramethylguanidine, 1,5- diazabicyclo[4.3.0]non-5-ene, l,8-diazabicyclo[5.4.0]undec-7-ene, alkoxides, and carbonates.
35. The method of claim 33, wherein the corticosteroid, the compound of formula (IB), and the base are reacted with a catalyst.
36. The method of claim 35, wherein the catalyst comprises 4-dimethylaminopyridine.
37. The method of claim 33, wherein the 21-hydroxy corticosteroid is selected from the group consisting of alclometasone, aldosterone, beclomethasone, betamethasone, clocortolone, hydrocortisone, budesonide, cortisone, desoximetasone, desonide, dexamethosone, flucloronide, fludrocortisone, flumethasone, flunisolide, fluocinolone acetonide, fluocortolone, fluprednisolone, flurandrenolide, halometasone, methylprednisolone, paramethasone, prednival, prednylidene, prednisolone, prednisone, triamcinolone, and triamcinolone acetonide.
38. The method of claim 33, wherein the 21-hydroxy corticosteroid comprises a 21- hydroxy glucocorticoid.
39. The method of claim 38, wherein the 21-hydroxy corticosteroid comprises prednisolone.
40. The method of claim 33, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
41. The method of claim 33, wherein: X is Cl or Br; and the corticosteroid, the compound of formula (IB), and the base are reacted with a catalyst.
42. The method of claim 41, wherein the 21-hydroxy corticosteroid comprises a 21- hydroxy glucocorticoid.
43. The method of claim 42, wherein the 21-hydroxy corticosteroid comprises prednisolone.
44. The method of claim 43, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
45. The method of claim 44, wherein the catalyst comprises 4-dimethylaminopyridine and the base comprises trimethylamine.
46. A compound of formula (I)
Figure imgf000026_0001
wherein:
R1 is selected from the group consisting of OH, Cl, Br, F, I, and -OC(O)R10; m is an integer from 0 to 4; n is an integer from 0 to 5;
R2 is independently selected at each occurrence from the group consisting of amino, substituted amino, halogen, Cι-6 alkyl, Cι-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR ;
R3 and R4 are independently selected at each occmxence from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, Cι-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R5 and R6 are independently selected from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR ;
R7 is independently selected at each occurrence from the group consisting of hydrogen, -C(O)R8, and -C(O)NR8R9;
R8 and R9 are independently selected at each occurrence from the group consisting of hydrogen and Cι-6 alkyl; and
R10 is selected from the group consisting of C1-6 alkyl, Ci-β chloroalkyl, alkoxy- substituted C1-6 alkyl, and aryl.
47. The compound of claim 46, wherein R1 is OH.
48. The compound of claim 46, wherein R1 is Cl or Br.
49. The compound of claim 47, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
50. The compound of claim 48, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
51. A method for producing a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative comprising:
(a) reacting a compound of formula (II)
Figure imgf000027_0001
wherein: m is an integer from 0 to 4; n is an integer from 0 to 5;
R2 is independently selected at each occurrence from the group consisting of amino, substituted amino, halogen, C1-6 alkyl, Ci-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R3 and R4 are independently selected at each occurrence from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, Cι-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, Cι-6 substituted alkylamino, and -OR7;
R5 and R6 are independently selected from the group consisting of hydrogen, amino, substituted amino, halogen, C1-6 alkyl, C1-6 haloalkyl, alkoxy, aryl, C1-6 alkylamino, C1-6 substituted alkylamino, and -OR7;
R7 is independently selected at each occurrence from the group consisting of hydrogen, -C(O)R8, and -C(O)NR8R9; and
R8 and R9 are independently selected at each occurrence from the group consisting of hydrogen and C1-6 alkyl; with acetic anhydride and nitric acid to form a compound of formula (IA)
Figure imgf000028_0001
wherein m, n, R2, R3, R4, R5, and R6 are as above in the compound of formula (II); (b) reacting the compound of formula (IA) with an acid anhydride or an acid chloride to form a compound of formula (IC)
Figure imgf000028_0002
wherein: m, n, R2, R3, R4, R5, and R6 are as above in the compound of formula (II); and R10 is selected from the group consisting of C1-6 alkyl, C1-6 chloroalkyl, alkoxy- substituted Ci-6 alkyl, and aryl; and
(c) reacting the compound of formula (IC) with a 21-hydroxyalkyl corticosteroid and a base to produce a 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivative.
52. The method of claim 51, wherein the base is selected from the group consisting of trimethylamine, pyridine, diisopropyl ethylamine, tetramethylguanidine, 1,5- diazabicyclo[4.3.0]non-5-ene, l,8-diazabicyclo[5.4.0]undec-7-ene, alkoxides, and carbonates.
53. The method of claim 51, wherein the corticosteroid, the compound of formula (IC), and the base are reacted with a catalyst.
54. The method of claim 53, wherein the catalyst comprises 4-dimethylaminopyridine.
55. The method of claim 51, wherein the 21-hydroxy corticosteroid is selected from the group consisting of alclometasone, aldosterone, beclomethasone, betamethasone, clocortolone, hydrocortisone, budesonide, cortisone, desoximetasone, desonide, dexamethosone, flucloronide, fludrocortisone, flumethasone, flunisolide, fluocinolone acetonide, fluocortolone, fluprednisolone, flurandrenolide, halometasone, methylprednisolone, paramethasone, prednival, prednylidene, prednisolone, prednisone, triamcinolone, and triamcinolone acetonide.
56. The method of claim 51, wherein the 21-hydroxy corticosteroid comprises a 21- hydroxy glucocorticoid.
57. The method of claim 56, wherein the 21-hydroxy corticosteroid comprises prednisolone.
58. The method of claim 51, wherein m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen.
59. The method of claim 51 , wherein: the base is selected from the group consisting of trimethylamine, pyridine, diisopropyl ethylamine, tetramethylguanidine, l,5-diazabicyclo[4.3.0]non-5-ene, 1,8- diazabicyclo[5.4.0]undec-7-ene, alkoxides, and carbonates; the corticosteroid, the compound of formula (IC), and the base are reacted with a catalyst comprising 4-dimethylaminopyridine; m is 0, n is 0, R5 is hydrogen, and R6 is hydrogen; and the 21-hydroxy corticosteroid comprises prednisolone.
PCT/US2002/016200 2001-05-21 2002-05-21 Method of purifying polycyclic dyes WO2002094942A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001113430 2001-05-21
RU2001113430/04A RU2209221C2 (en) 2001-05-21 2001-05-21 Polycyclic dye purification method

Publications (2)

Publication Number Publication Date
WO2002094942A1 true WO2002094942A1 (en) 2002-11-28
WO2002094942A9 WO2002094942A9 (en) 2003-04-10

Family

ID=20249721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016200 WO2002094942A1 (en) 2001-05-21 2002-05-21 Method of purifying polycyclic dyes

Country Status (2)

Country Link
RU (1) RU2209221C2 (en)
WO (1) WO2002094942A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10026553B2 (en) 2015-10-21 2018-07-17 Capacitor Sciences Incorporated Organic compound, crystal dielectric layer and capacitor

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2544696C2 (en) * 2012-11-02 2015-03-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Тамбовский государственный технический университет" ФГБОУ ВПО ТГТУ Method of removing water-soluble admixtures from suspensions of organic products
US9941051B2 (en) 2015-06-26 2018-04-10 Capactor Sciences Incorporated Coiled capacitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448446A (en) * 1981-12-09 1984-05-15 The Sherwin-Williams Company Process for the purification of triphenylmethane compounds and pressure sensitive copysheet containing same
DE3520806A1 (en) * 1985-06-11 1986-12-11 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING PIGMENTS OF THE ANTHANTHRON RANGE
US4678613A (en) * 1981-12-09 1987-07-07 Pmc Specialties Group, Inc. Process for the purification of triphenylmethane compounds
US4734137A (en) * 1985-05-10 1988-03-29 Toyo Soda Manufacturing Co., Ltd. Process for preparation of organic pigments
CN1306044A (en) * 2000-12-13 2001-08-01 陈勇 Process for preparing ginger yellow pigment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448446A (en) * 1981-12-09 1984-05-15 The Sherwin-Williams Company Process for the purification of triphenylmethane compounds and pressure sensitive copysheet containing same
US4678613A (en) * 1981-12-09 1987-07-07 Pmc Specialties Group, Inc. Process for the purification of triphenylmethane compounds
US4734137A (en) * 1985-05-10 1988-03-29 Toyo Soda Manufacturing Co., Ltd. Process for preparation of organic pigments
DE3520806A1 (en) * 1985-06-11 1986-12-11 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING PIGMENTS OF THE ANTHANTHRON RANGE
CN1306044A (en) * 2000-12-13 2001-08-01 陈勇 Process for preparing ginger yellow pigment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [online] CHEN Y.: "Process for preparing curcumin", XP002957876, accession no. CAS Database accession no. 2002:494407 *
DATABASE HCAPLUS [online] SPIETSCHKA ET AL.: "Anthanthrone pigment purification", XP002957875, accession no. CAS Database accession no. 1987:121394 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10026553B2 (en) 2015-10-21 2018-07-17 Capacitor Sciences Incorporated Organic compound, crystal dielectric layer and capacitor

Also Published As

Publication number Publication date
RU2209221C2 (en) 2003-07-27
WO2002094942A9 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
EP1169337B1 (en) Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction
JPH01104095A (en) Manufacture of methylene derivative of androsta-1,4-diene-3,17-dione
EP1395544B1 (en) Methods of making 21- 4'-(nitrooxyalkyl) benzoate corticosteroid derivatives and intermediates useful in the synthesis thereof
WO2002094942A1 (en) Method of purifying polycyclic dyes
US20050090675A1 (en) Process for preparing highly pure androstane 17-beta-carboxylic acids and 17-beta-carbothioic acid fluoromethyl esters thereof
NZ239141A (en) 4-amino-delta-4,6-steroids; preparatory processes and pharmaceutical compositions
US5486626A (en) Process for the preparation of 3β-aminocholanic acid derivatives
US4155917A (en) Process for preparing D-homo oxasteroids
US4412953A (en) Process for preparing 16α-hydroxy-17α-aminopregnane derivatives
JPS636559B2 (en)
CA2584052C (en) Process for the esterification of a carbothioic acid
US5583228A (en) 17-halogeno-4-azaandrostene derivatives and process for the preparation thereof
US4430270A (en) Process for the production of delta 4-C21-steroid compounds
IE58786B1 (en) A selective acylation process
DE2603545A1 (en) NEW PREDNISOLONE AND PREDNISON DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
JP2980992B2 (en) Method for producing 6-halogeno-2-oxapregna-4,6-dien-3-one compound
JPS6118559B2 (en)
JP2893906B2 (en) Method for producing unsaturated ketone compound
JP2010513252A (en) A novel method for diastereoselective formation of chiral primary amines on steroids
EP0983247A1 (en) Method for producing aromatic bisimides
JPS5821661A (en) Sulfonate derivative and its preparation
JPH0625281A (en) 2-deoxy-3-acylbrassinosteroid
EP0469275A2 (en) 3-Oxo or 3-hydroxy derivatives of 17-alpha, 20-epoxy pregnan-20-carboxylic acids, preferably isocyanate derivatives, their use and process for preparing 3-oxo or 3-hydroxy, 17-alpha hydroxy-20-oxo pregnanes and their esters
JPS6383096A (en) Production of steroid compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: DUE TO A SCANNING ERROR DURING THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION, REPLACE ALL PAGES BY CORRECT PAGES (12 PAGES)

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)